Table 3:
Clinical indications for examinations in those patients with signal changes in the DVA drainage territory (signal) and those without (no signal)
| Clinical Indication | Signal | % | No Signal | % | P* |
|---|---|---|---|---|---|
| Follow-up of previous abnormality, NOS† | 0 | 0.0 | 4 | 2.9 | NS |
| Anosmia | 1 | 4.8 | 0 | 0.0 | NS |
| Assess for metastatic disease, known malignancy | 1 | 4.8 | 11 | 8.1 | NS |
| Ataxia | 0 | 0.0 | 2 | 1.5 | NS |
| Arteriovenous malformation | 0 | 0.0 | 1 | 0.7 | NS |
| Facial nerve palsy | 0 | 0.0 | 1 | 0.7 | NS |
| CM | 0 | 0.0 | 3 | 2.2 | NS |
| Dizziness, vertigo | 0 | 0.0 | 4 | 2.9 | NS |
| DVA | 1 | 4.8 | 2 | 1.5 | NS |
| Encephalitis | 0 | 0.0 | 1 | 0.7 | NS |
| Headache | 1 | 4.8 | 31 | 22.8 | .078 |
| Histoplasmosis | 0 | 0.0 | 1 | 0.7 | NS |
| Hydrocephalus | 0 | 0.0 | 2 | 1.5 | NS |
| ICH | 0 | 0.0 | 3 | 2.2 | NS |
| Intracranial tumor follow-up | 4 | 19.0 | 31 | 22.8 | NS |
| Mental status changes | 1 | 4.8 | 4 | 2.9 | NS |
| Multiple sclerosis | 1 | 4.8 | 5 | 3.7 | NS |
| Movement disorder | 0 | 0.0 | 2 | 1.5 | NS |
| Pituitary dysfunction | 0 | 0.0 | 3 | 2.2 | NS |
| Sarcoid | 1 | 4.8 | 5 | 3.7 | NS |
| Syncope | 1 | 4.8 | 0 | 0.0 | NS |
| Seizures | 6 | 28.6 | 16 | 11.8 | .083 |
| Sensorineural hearing loss | 1 | 4.8 | 4 | 2.9 | NS |
| TIA/strokelike symptoms | 2 | 9.5 | 4 | 2.9 | NS |
| Trauma | 0 | 0.0 | 3 | 2.2 | NS |
| Visual changes | 0 | 0.0 | 4 | 2.9 | NS |
Note:—NOS indicates not otherwise specified; NS, not significant; ICH, intracranial hemorrhage; TIA, transient ischemic attack.
*
P values are from the Fisher exact test, NS with P > .1.
†
Previously identified abnormality on another imaging test (prior CT or MR imaging), NOS. MR imaging performed for follow-up purposes.